title: Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF.
authors: Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, Italy; and Department of Medicine, ASL 1 Avezzano-Sulmona-L'Aquila, Italy. francescocarubbi@libero.it.
authors: Francesco
authors: F
authors: Carubbi
authors: Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, Italy.
authors: Paola
authors: P
authors: Cipriani
authors: Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, Italy.
authors: Paola
authors: P
authors: Di Benedetto
authors: Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, Italy.
authors: Piero
authors: P
authors: Ruscitti
authors: Department of Medicine, Rheumatology Unit, University of Perugia, Italy.
authors: Alessia
authors: A
authors: Alunno
authors: Department of Medicine, Rheumatology Unit, University of Perugia, Italy.
authors: Roberto
authors: R
authors: Gerli
authors: Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, Italy.
authors: Roberto
authors: R
authors: Giacomelli
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D053264:B-Cell Activating Factor / Q000378:metabolism*; D006801:Humans; D000069283:Rituximab / Q000627:therapeutic use*; D012469:Salivary Glands / Q000378:metabolism*; D012793:Sialadenitis / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D018501:Antirheumatic Agents; D053264:B-Cell Activating Factor; C505719:TNFSF13B protein, human; D000069283:Rituximab